8-KOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Oct 31, 2013)

Filed October 31, 2013For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on October 31, 2013, to report on the closing of a significant debt offering. The company successfully issued $1.5 billion in aggregate principal amount of notes across three tranches: $500 million in 1.750% notes due 2019, $500 million in 3.250% notes due 2023, and $500 million in 4.500% notes due 2044. This debt issuance, agreed upon on October 24, 2013, and closed on October 31, 2013, was conducted under an underwriting agreement with several major financial institutions and was registered with the SEC. The primary purpose of this filing is to disclose the details of this financing transaction and to provide access to the related legal and underwriting documents, offering investors insight into the company's capital structure and its access to public debt markets.

Key Highlights

  • 1BMY closed a $1.5 billion debt offering on October 31, 2013.
  • 2The offering consisted of three tranches of notes: $500M of 1.750% notes due 2019, $500M of 3.250% notes due 2023, and $500M of 4.500% notes due 2044.
  • 3The notes were issued under an underwriting agreement dated October 24, 2013.
  • 4The issuance was registered under the Securities Act of 1933 via a Form S-3 registration statement.
  • 5Key documents related to the offering, including the underwriting agreement and supplemental indenture, are filed as exhibits.
  • 6This filing provides transparency on BMY's capital raising activities and debt obligations.

Frequently Asked Questions

The primary purpose of this 8-K filing was to report on the closing of Bristol-Myers Squibb's $1.5 billion debt offering and to provide the necessary documentation and disclosures related to this transaction.

BMY issued $1.5 billion in aggregate principal amount of notes: $500 million of 1.750% notes due 2019, $500 million of 3.250% notes due 2023, and $500 million of 4.500% notes due 2044.

The underwriters included Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., BNP Paribas Securities Corp., Credit Suisse Securities (USA) LLC, and RBS Securities Inc., acting as representatives of the several underwriters.

This debt issuance indicates the company's ability to access capital markets to fund its operations or strategic initiatives. It also affects the company's leverage and future interest expenses. Investors can review the terms of the notes and the associated filings to understand the impact on the company's financial structure.